Financials data is unavailable for this security.
View more
Year on year Jianmin Pharmaceutical Group Co Ltd grew revenues 15.72% from 3.64bn to 4.21bn while net income improved 27.78% from 408.08m to 521.46m.
| Gross margin | 43.71% |
|---|---|
| Net profit margin | 12.58% |
| Operating margin | 13.65% |
| Return on assets | 13.17% |
|---|---|
| Return on equity | 23.77% |
| Return on investment | 23.24% |
More ▼
Cash flow in CNYView more
In 2023, Jianmin Pharmaceutical Group Co Ltd increased its cash reserves by 64.57%, or 105.39m. The company earned 268.39m from its operations for a Cash Flow Margin of 6.37%. In addition the company used 77.31m on investing activities and also paid 85.70m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 15.04 |
|---|---|
| Tangible book value per share | 14.82 |
More ▼
Balance sheet in CNYView more
| Current ratio | 1.43 |
|---|---|
| Quick ratio | 1.26 |
| Total debt/total equity | 0.1485 |
|---|---|
| Total debt/total capital | 0.1287 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 20.00% and 27.21%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked above the industry average relative to its peers.
| Div yield(5 year avg) | 1.49% |
|---|---|
| Div growth rate (5 year) | 43.10% |
| Payout ratio (TTM) | 36.20% |
| EPS growth(5 years) | 45.13 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 7.27 |
More ▼
